Screener
Aktis Oncology, Inc. AKTS Q1 2027 earnings
Reported November 12, 2026 · Before market open
Revenue$3.9MMiss by $968.5K
EPS-$0.54Miss by $0.07
Revenue estimate$4.9M
EPS estimate-$0.47
“With the initiation of the BActinium-2 trial of AKY-2519, we now have three clinical trials underway in the U.S. across two novel targets, Nectin-4 and B7-H3, which are both implicated in a range of solid tumor types. We also opened the first backfill cohorts in our ongoing NECTINIUM-2 and BActinium-1 trials to further characterize safety and preliminary antitumor activity at the selected doses, while dose escalation continues in both studies. This substantial clinical progress is a testament to our ability to execute rapidly with quality across multiple clinical trials and positions Aktis for a data-rich 2027.”
Next report
Date not yet announcedVersus estimates
FAQ
- When did Aktis Oncology, Inc. report Q1 2027 earnings?
- Aktis Oncology, Inc. (AKTS) reported Q1 2027 earnings on November 12, 2026 before market open.
- What were Aktis Oncology, Inc.'s Q1 2027 revenue and EPS?
- Aktis Oncology, Inc. reported revenue of $3.9M and eps of $-0.54 for Q1 2027.
- Did Aktis Oncology, Inc. beat estimates in Q1 2027?
- Revenue missed the consensus estimate of $4.9M by $968.5K. EPS missed the consensus estimate of $-0.47 by $0.07.
- Where can I find Aktis Oncology, Inc.'s Q1 2027 SEC filings?
- You can read the 8-K earnings release (0001193125-26-457045) and the 10-Q periodic report (0001193125-26-457054) directly on SEC EDGAR. The filing index links above go to sec.gov.
